Archives for 

U.S. District Court Decisions

CELLTRION FILES RESPONSE BRIEF IN INFLIXIMAB APPEAL

Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Janssen v. Celltrion (infliximab)  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
As we previously reported, in Janssen v. Celltrion, Janssen appealed the district court’s partial final judgment that Janssen’s ‘471 patent, relating to monoclonal antibodies including infliximab, is invalid. As we also previously reported, Janssen filed its opening appeal […]

View More

Janssen v. Celltrion: Janssen Appeals Judgment Invalidating the ’471 Patent

Approved Biosimilar Products  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
As we previously reported, on September 26, 2016, the district court in Janssen v. Celltrion entered partial final judgment that the ’471 patent, asserted by Janssen, was invalid.  Today, Janssen filed a notice that they […]

View More

Amgen v. Hospira (epoetin alfa): District Court Lets in New Infringement Theories, Not New Defendants

Amgen v. Hospira (epoetin alfa)  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
As we previously reported, Amgen has sought to amend its complaint regarding Hospira’s planned epoetin alfa biosimilar to add three new defendants and two theories of infringement.  On October 3, 2016, Judge Andrews granted-in-part […]

View More

Breaking News: Apotex Does not Infringe Amgen’s Filgrastim and Pegfilgrastim Patent; Apotex is Permanently Enjoined From Launch Until It Provides 180 Days’ Notice

Amgen v. Apotex (pegfilgrastim)  •  Patent Dance  •  U.S. District Court Decisions
The District Court for the Southern District of Florida today ruled that Apotex’s proposed filgrastim and pegfilgrastim products will not infringe the asserted claims of Amgen’s ’138 patent (U.S. Patent. No. 8,952,138).  The court, […]

View More

Litigation Update: Motions in Janssen v. Celltrion for Entry of Final Judgment and Case Scheduling

Amgen v. Hospira (epoetin alfa)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Janssen v. Celltrion (infliximab)  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
  As we posted previously, the District Court in Janssen v. Celltrion has ruled that the ‘471 patent is invalid for obviousness-type double patenting on the two grounds raised in the defendants’ motions for summary judgment on that […]

View More

BREAKING NEWS: Summary Judgment, Claim Construction, Consolidation, Bifurcation, and Trial Schedule Order Issued in Janssen v. Celltrion

Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
Following three days of hearings in Janssen v. Celltrion, the District Court for the District of Massachusetts (J. Wolf) today issued a memorandum order summarizing the Court’s rulings on several pending motions in […]

View More

Court Denies Hospira’s Motion to Dismiss BPCIA Notice Claims in Amgen v. Hospira

Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
  The District Court (D. Del., J. Andrews) has denied Hospira’s Motion to Dismiss in Amgen v. Hospira. As we’ve covered previously (see our posts here and here), Hospira moved to dismiss Count I of Amgen’s amended […]

View More